S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The Real Reason They Murdered JFK? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The Real Reason They Murdered JFK? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The Real Reason They Murdered JFK? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
The Real Reason They Murdered JFK? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
The Real Reason They Murdered JFK? (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
The Real Reason They Murdered JFK? (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
TSE:CTX

Crescita Therapeutics (CTX) Stock Forecast, Price & News

C$0.63
-0.04 (-5.97%)
(As of 09/29/2023 ET)
Compare
Today's Range
C$0.63
C$0.66
50-Day Range
C$0.63
C$0.73
52-Week Range
C$0.50
C$0.79
Volume
3,970 shs
Average Volume
22,583 shs
Market Capitalization
C$12.83 million
P/E Ratio
12.60
Dividend Yield
N/A
Price Target
N/A

CTX stock logo

About Crescita Therapeutics (TSE:CTX) Stock

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

CTX Price History

CTX Stock News Headlines

Closing Bell: Crescita Therapeutics Inc down on Friday (CTX)
Closing Bell: Crescita Therapeutics Inc flat on Tuesday (CTX)
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
Crescita Reports Second Quarter 2023 Results
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
Crescita Reports First Quarter 2023 Results
Crescita Therapeutics Q4 Profit Rises, But Revenues Decline
Crescita Reports Q4 and Fiscal 2022 Results
CTX:CA Crescita Therapeutics Inc.
Crescita Reports Third Quarter 2022 Results
Crescita Therapeutics Inc
Crescita Reports Second Quarter 2022 Results
See More Headlines
Receive CTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crescita Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

Net Income
C$1.06 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$21.83 million
Cash Flow
C$0.53 per share
Book Value
C$1.01 per share

Miscellaneous

Free Float
N/A
Market Cap
C$12.83 million
Optionable
Not Optionable
Beta
1.89
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Serge Verreault B.A.
    M.B.A., Pres, CEO & Director
  • Mr. Jose DaRocha C.A.
    CPA, Chief Financial Officer
  • Mr. Francois Lafortune
    Exec. VP & GM













CTX Stock - Frequently Asked Questions

How have CTX shares performed in 2023?

Crescita Therapeutics' stock was trading at C$0.66 at the beginning of 2023. Since then, CTX stock has decreased by 4.5% and is now trading at C$0.63.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Crescita Therapeutics own?
What is Crescita Therapeutics' stock symbol?

Crescita Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CTX."

How do I buy shares of Crescita Therapeutics?

Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Crescita Therapeutics' stock price today?

One share of CTX stock can currently be purchased for approximately C$0.63.

How much money does Crescita Therapeutics make?

Crescita Therapeutics (TSE:CTX) has a market capitalization of C$12.83 million and generates C$21.83 million in revenue each year. The company earns C$1.06 million in net income (profit) each year or C$0.05 on an earnings per share basis.

How can I contact Crescita Therapeutics?

Crescita Therapeutics' mailing address is 7560 Airport Rd Unit 10, MISSISSAUGA, ON L4T 4H4, Canada. The official website for the company is www.crescitatherapeutics.com. The company can be reached via phone at +1-905-6734295.

This page (TSE:CTX) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -